BioWorld

Sep. 25, 2007

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today) Read More

Celgene Paying Array $40M Up Front For Drug Discovery

Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Elixir Aiming For Public Markets With $86M IPO

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...